About
Mental-Heal by Abital is developing a novel oral antipsychotic drug, PGW-5, for the treatment of schizophrenia and bipolar disorder. PGW-5 is a neuroleptic, multi-target agent that is potentially effective for the treatment of schizophrenia symptoms and other cognitive deficits and mood disorders. The possible mechanisms underlying the differential effects of the drugs may involve the brain glutamate NMDA (N-Methyl-D-Aspartate receptor) system as well as neurotrophic factors and food intake regulating peptides. Early scientific work in animal models has shown that PGW-5 has anxiolytic and antidepressant activity and improves impaired social performance in PCP-treated mice.
Funding history · 1 round · — total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Mental Heal's primary focus?
- Mental Heal is developing PGW-5, a novel oral antipsychotic drug for treating schizophrenia and bipolar disorder.
- When was Mental Heal founded?
- Mental Heal was founded in October 2012.
- What is the current operational status of Mental Heal?
- Mental Heal has been inactive since January 2016.
- Where is Mental Heal headquartered?
- Mental Heal is headquartered in Tel Aviv-Yafo, Israel.
- What is the employee count for Mental Heal?
- Mental Heal has 2 employees.
- Has Mental Heal secured any funding?
- Mental Heal has completed a Seed funding round with investors including the Office of the Chief Scientist and Abital. For full financing history, refer to startupim.
- What product is Mental Heal developing?
- Mental Heal is developing PGW-5, an oral antipsychotic drug.
- Who is a founder of Mental Heal?
- Santiago Ini is a founder of Mental Heal.